AU4914600A - Method for treating tnf-receptor type-2-induced diseases - Google Patents

Method for treating tnf-receptor type-2-induced diseases

Info

Publication number
AU4914600A
AU4914600A AU49146/00A AU4914600A AU4914600A AU 4914600 A AU4914600 A AU 4914600A AU 49146/00 A AU49146/00 A AU 49146/00A AU 4914600 A AU4914600 A AU 4914600A AU 4914600 A AU4914600 A AU 4914600A
Authority
AU
Australia
Prior art keywords
receptor type
induced diseases
treating tnf
tnf
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU49146/00A
Inventor
Thomas Hehlgans
Daniela N. Mannel
Carola Seitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of AU4914600A publication Critical patent/AU4914600A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU49146/00A 1999-05-07 2000-04-28 Method for treating tnf-receptor type-2-induced diseases Abandoned AU4914600A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19922444A DE19922444A1 (en) 1999-05-07 1999-05-07 Procedure for the treatment of TNF-receptor mediated diseases
DE19922444 1999-05-07
PCT/EP2000/003866 WO2000067790A1 (en) 1999-05-07 2000-04-28 Method for treating tnf-receptor type-2-induced diseases

Publications (1)

Publication Number Publication Date
AU4914600A true AU4914600A (en) 2000-11-21

Family

ID=7908195

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49146/00A Abandoned AU4914600A (en) 1999-05-07 2000-04-28 Method for treating tnf-receptor type-2-induced diseases

Country Status (4)

Country Link
EP (1) EP1206279A1 (en)
AU (1) AU4914600A (en)
DE (1) DE19922444A1 (en)
WO (1) WO2000067790A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741667A (en) * 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors

Also Published As

Publication number Publication date
WO2000067790A1 (en) 2000-11-16
EP1206279A1 (en) 2002-05-22
DE19922444A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
AU1294401A (en) Methods for treating fibroproliferative diseases
AU6367099A (en) Improved process for water treatment
AU7085100A (en) Method for treating otic disorders
AU9035498A (en) Method for treating pain
AU2002232919A1 (en) Method for treating fibrotic diseases or other indications
AU6850700A (en) Method for treating architectural material
AU2695300A (en) Waste treating method
AU2042301A (en) 1-aminoalkyl-1H-indoles for treating glaucoma
AU1028001A (en) Secretin fragments for treating autism
AU5733099A (en) Method for treating ocular neovascular diseases
AU7750100A (en) Method for the treatment of obesity
AUPQ232599A0 (en) Drug for treating fractures
AU4515001A (en) Compositions and methods for locally treating inflammatory diseases
AUPP870999A0 (en) Method of treatment of equine disease
AU9034798A (en) Method for treating pain
AU2001238288A1 (en) Method and compositions for treating fibrotic diseases
AU4914600A (en) Method for treating tnf-receptor type-2-induced diseases
AU2924400A (en) Plant treatment method
AU6234000A (en) Methods for treating autoimmune diseases
AU4598400A (en) Method of treatment
AU2382601A (en) Novel method of treatment
AU1036801A (en) Agent for treating cephalic pain
AU4157400A (en) Method for heat treatment
AU2231801A (en) Process for treating sodium aluminosilicate
AU1784701A (en) Method of treating neuroblastoma

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase